A study found the combination of monoclonal antibodies casirivimab and imdevimab significantly reduced the risk of developing a symptomatic infection compared with placebo


According to a study published in JAMA, the combination of monoclonal antibodies casirivimab and imdevimab in asymptomatic, SARS-CoV-2 infected participants who were seronegative at baseline significantly reduced the risk of developing a symptomatic infection compared with placebo.

The primary efficacy analysis included 204 household contacts with confirmed SARS-CoV-2 quantitative reverse transcription polymerase chain reaction (RT-qPCR) positivity at baseline, who were randomised to receive 1200 mg of subcutaneous casirivimab and imdevimab (n=100) or placebo (n=104). The primary endpoint was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period.

The results showed that 29 percent of participants who received casirivimab and imdevimab progressed to symptomatic disease, compared to 42.3 per cent receiving placebo (odds ratio [OR] 0.54; 95% confidence interval [CI] 0.30–0.97; P=.04).

Secondary outcomes were also favourable for participants receiving casirivimab and imdevimab regarding the duration of symptomatic infection, duration of RT-qPCR-detectable SARS-CoV-2 in the nasopharynx, and proportion of patients with COVID-19-related hospitalisations or emergency department visits.

These findings indicate that subcutaneous casirivimab and imdevimab is effective in preventing symptomatic COVID-19 in close-contact settings, highlighting the potential clinical relevance for the use of monoclonal antibody therapies in the early treatment of COVID‑19, the authors say.

This article originally appeared on Univadis, part of the Medscape Professional Network.


Lead image: Corona Borealis/stock.adobe.com

Image 1: Corona Borealis/stock.adobe.com